Enantioselective Synthesis and Profiling of Two Novel Diazabicyclooctanone β-Lactamase Inhibitors.

ACS Med Chem Lett

Infection Innovative Medicines, AstraZeneca Pharmaceuticals , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.

Published: October 2014

The enantioselective synthesis of two novel cyclopropane-fused diazabicyclooctanones is reported here. Starting from butadiene monoxide, the key enone intermediate 7 was prepared in six steps. Subsequent stereoselective introduction of the cyclopropane group and further transformation led to compounds 1a and 1b as their corresponding sodium salt. The great disparity regarding their hydrolytic stability was rationalized by the steric interaction between the cyclopropyl methylene and urea carbonyl. These two novel β-lactamase inhibitors were active against class A, C, and D enzymes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190641PMC
http://dx.doi.org/10.1021/ml500284kDOI Listing

Publication Analysis

Top Keywords

enantioselective synthesis
8
β-lactamase inhibitors
8
synthesis profiling
4
profiling novel
4
novel diazabicyclooctanone
4
diazabicyclooctanone β-lactamase
4
inhibitors enantioselective
4
synthesis novel
4
novel cyclopropane-fused
4
cyclopropane-fused diazabicyclooctanones
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!